{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T09:16:37Z","timestamp":1795079797275,"version":"4.10.2"},"reference-count":45,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2005,1,28]],"date-time":"2005-01-28T00:00:00Z","timestamp":1106870400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2005,2]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:bold>Background<\/jats:bold> :\u2002Immunodeficiency syndromes associated with a Crohn's\u2010like illness suggest innate immune defects may lead to Crohn's disease. Anecdotal cases using haemopoietic colony\u2010stimulating factors report improvement in intestinal disease associated with these syndromes.<\/jats:p><jats:p><jats:bold>Aim<\/jats:bold> :\u2002To test the safety and efficacy of recombinant human granulocyte colony\u2010stimulating factor in active Crohn's disease.<\/jats:p><jats:p><jats:bold>Methods<\/jats:bold> :\u2002In an open\u2010labelled 12\u2010week trial, patients with a Crohn's Disease Activity Index between 220 and 450 were treated with recombinant human granulocyte colony\u2010stimulating factor (filgrastim, Neupogen). Concomitant immunosuppressants were prohibited except prednisone \u226420\u2003mg\/day. Patient's received recombinant human granulocyte colony\u2010stimulating factor 300\u2003mcg daily subcutaneously adjusted to achieve an absolute neutrophil count between 25 and 35\u2003\u00d7\u200310<jats:sup>9<\/jats:sup>\/L.<\/jats:p><jats:p><jats:bold>Results<\/jats:bold> :\u2002Twenty patients were enrolled with a mean initial Crohn's Disease Activity Index of 307 (range: 234\u2013428). Fifteen patients (75%) completed 8\u2003weeks; 13 patients (65%) completed 12\u2003weeks with the mean Crohn's Disease Activity Index for patients continuing through those times of 196 (range: 36\u2013343) and 162 (range: 20\u2013308), respectively. At week 12, 11 patients (55%) demonstrated a decrease of at least 70\u2003points; five (25%) achieved a sustained remission. The mean decrease was statistically significant at each assessment time\u2010point. Three of four patients with fistulae had a positive response. Adverse effects included bone pain, mostly mild resolving with continued treatment. One patient was hospitalized with a viral\u2010like syndrome but it is uncertain if this was treatment related.<\/jats:p><jats:p><jats:bold>Conclusion<\/jats:bold> :\u2002Recombinant human granulocyte colony\u2010stimulating factor is safe and potentially effective therapy for active Crohn's disease.<\/jats:p>","DOI":"10.1111\/j.1365-2036.2005.02287.x","type":"journal-article","created":{"date-parts":[[2005,2,15]],"date-time":"2005-02-15T01:24:43Z","timestamp":1108430683000},"page":"391-400","source":"Crossref","is-referenced-by-count":70,"title":["An open\u2010labelled study of granulocyte colony\u2010stimulating factor in the treatment of active Crohn's disease"],"prefix":"10.1111","volume":"21","author":[{"given":"J. R.","family":"Korzenik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. K.","family":"Dieckgraefe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2005,1,28]]},"reference":[{"key":"e_1_2_21_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/0016-5085(82)90023-3"},{"key":"e_1_2_21_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005176-198409000-00028"},{"key":"e_1_2_21_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005176-198506000-00030"},{"key":"e_1_2_21_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1651-2227.1995.tb13575.x"},{"key":"e_1_2_21_6_2","doi-asserted-by":"publisher","DOI":"10.3109\/15513819009067103"},{"key":"e_1_2_21_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(95)70519-8"},{"key":"e_1_2_21_8_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.38.4.619"},{"key":"e_1_2_21_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199206183262504"},{"key":"e_1_2_21_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01799948"},{"key":"e_1_2_21_11_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.39.4.605"},{"key":"e_1_2_21_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004836-198710000-00015"},{"key":"e_1_2_21_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0954-6820.1988.tb15887.x"},{"key":"e_1_2_21_14_2","first-page":"367","article-title":"Neutropenia primitive et congenital et maladie de Crohn","volume":"39","author":"Vannier J","year":"1982","journal-title":"Arch Fr Pediatr"},{"key":"e_1_2_21_15_2","first-page":"1638","article-title":"Crohn's disease associated with cyclic neutropenia","volume":"87","author":"Lamport RD","year":"1992","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_21_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004836-199106000-00016"},{"key":"e_1_2_21_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(98)84038-9"},{"key":"e_1_2_21_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(98)84037-7"},{"key":"e_1_2_21_19_2","doi-asserted-by":"crossref","first-page":"S160","DOI":"10.1007\/BF03545616","article-title":"Inflammatory bowel disease in glycogen storage disease type 1b","volume":"25","author":"Schulman H","year":"1995","journal-title":"Pediatr Radiol"},{"key":"e_1_2_21_20_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1005541700805"},{"key":"e_1_2_21_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01957525"},{"key":"e_1_2_21_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(86)80572-8"},{"key":"e_1_2_21_23_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.42.1.127"},{"key":"e_1_2_21_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/00043426-199302000-00008"},{"key":"e_1_2_21_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(05)80290-2"},{"key":"e_1_2_21_26_2","doi-asserted-by":"publisher","DOI":"10.1203\/00006450-199401000-00017"},{"key":"e_1_2_21_27_2","doi-asserted-by":"publisher","DOI":"10.1007\/s004320050170"},{"key":"e_1_2_21_28_2","doi-asserted-by":"publisher","DOI":"10.1089\/107999000750053753"},{"key":"e_1_2_21_29_2","doi-asserted-by":"publisher","DOI":"10.1097\/00062752-199704030-00005"},{"key":"e_1_2_21_30_2","doi-asserted-by":"publisher","DOI":"10.1086\/595866"},{"key":"e_1_2_21_31_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.92.13.5965"},{"key":"e_1_2_21_32_2","first-page":"222","article-title":"Complement and function of neutrophils in chronic inflammatory bowel disease","volume":"33","author":"Elmgreen J.","year":"1986","journal-title":"Dan Med Bull"},{"key":"e_1_2_21_33_2","doi-asserted-by":"publisher","DOI":"10.1097\/00062752-199704030-00011"},{"key":"e_1_2_21_34_2","doi-asserted-by":"publisher","DOI":"10.1159\/000074517"},{"key":"e_1_2_21_35_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004836-199706000-00015"},{"key":"e_1_2_21_36_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199901213400317"},{"key":"e_1_2_21_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(76)91024-2"},{"key":"e_1_2_21_38_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.22.10.817"},{"key":"e_1_2_21_39_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.29.2.223"},{"key":"e_1_2_21_40_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.32.1.55"},{"key":"e_1_2_21_41_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02088341"},{"key":"e_1_2_21_42_2","doi-asserted-by":"publisher","DOI":"10.3109\/00365528509088887"},{"key":"e_1_2_21_43_2","doi-asserted-by":"publisher","DOI":"10.1038\/35079114"},{"key":"e_1_2_21_44_2","doi-asserted-by":"publisher","DOI":"10.1165\/ajrcmb.13.1.7541223"},{"key":"e_1_2_21_45_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V86.12.4422.bloodjournal86124422"},{"key":"e_1_2_21_46_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V85.9.2482.bloodjournal8592482"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2005.02287.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2036.2005.02287.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T21:08:36Z","timestamp":1697231316000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2005.02287.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,1,28]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2005,2]]}},"alternative-id":["10.1111\/j.1365-2036.2005.02287.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2005.02287.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,1,28]]}}}